Kicker escribió:XOMA -35%![]()
XOMA Ltd. (XOMA) announced that its Phase 2b trial of XOMA 052 in Type 2 diabetes patients did not achieve the primary endpoint of reduction in glycosylated hemoglobin, or HbA1c, after six monthly treatments with XOMA 052 compared to placebo.
Kicker, vister el after....
http://www.nasdaq.com/aspxcontent/Exten ... type=after